ATAI Life Sciences
ATAI

$1.19

2.88%

Market Cap: $200M

About: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Employees: 83

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

11% more call options, than puts

Call options by funds: $200K | Put options by funds: $180K

0% more funds holding

Funds holding: 87 [Q1] → 87 (+0) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 15

1.92% less ownership

Funds ownership: 9.05% [Q1] → 7.13% (-1.92%) [Q2]

13% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 16

46% less capital invested

Capital invested by funds: $29.6M [Q1] → $15.9M (-$13.7M) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$15

1,161%

upside

Avg. target

$15

1,161%

upside

High target

$15

1,161%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target	1,161%upside $15	Buy Reiterated	30 Aug 2024
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target	1,161%upside $15	Buy Reiterated	31 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about ATAI published over the past 30 days

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company's participation:

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Psychedelic Stock Deep Dive: Atai Life Sciences

After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover with a unique company structure and diverse pipeline that could minimize risk. Atai's stock is at historic lows, but with several upcoming Phase 2 milestones, a long-term position in ATAI could be a smart move.

Psychedelic Stock Deep Dive: Atai Life Sciences

Proactive Investors

atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI

atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' chief scientific officer Dr Srinivas Rao joined Proactive to discuss the company's latest clinical trial results. Dr Rao detailed the positive outcomes from the Phase 1B trial of the VLS-01 (oral DMT) program, emphasizing the drug's excellent tolerability and potential as a best-in-class treatment option.

atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI

Proactive Investors

atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has been awarded a 'Buy' rating from Jefferies analysts as the company's pipeline of mental health therapies enters a catalyst-rich period. “atai's pipeline of psychedelics (and non-psychedelics) has the potential to safely, profoundly, and durably treat tough $1 billion-plus in central nervous systems indications,” analysts wrote in a note to clients.

atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead

Proactive Investors

atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has provided an update on its research activities and told investors it has cash, marketable securities, and committed term loan funding available which is expected to fund its operations into 2026. In addition to announcing its second quarter financial results, atai on Tuesday unveiled positive preliminary Phase 1b trial results for VLS-01, its proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT) that is applied to the buccal surface.

atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE'24 • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE'24 • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced second quarter 2024 financial results and provided corporate updates. “Over the past quarter, we've made significant strides to advance our pipeline, with key updates from our VLS-01 and EMP-01 programs,” stated Dr. Srinivas Rao, Co-Chief Executive Officer and Co-founder of atai.

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company's participation: Format: Fireside chat and 1x1 investor meetings Date and Time: Fireside chat on Wednesday August 14 at 11:00 A.M.

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

Zacks Investment Research

atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know

atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know

3 Dirt-Cheap Drug Developers With Blockbuster Potential

One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results.

3 Dirt-Cheap Drug Developers With Blockbuster Potential

See News Rankings